Please use this identifier to cite or link to this item:
|Title:||Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis|
Vivian P. Bykerk
Dianne P. Mosher
Janet E. Pope
J. Carter Thorne
Cathy Elizabeth Flanagan
University of Toronto
Centre Hospitalier de L'Universite de Montreal
University of Calgary
St. Joseph's Health Care London
The University of British Columbia
University of Ottawa, Canada
The Arthritis Program Research Group Inc.
Toronto General Research Institute University of Toronto
|Keywords:||Immunology and Microbiology;Medicine|
|Citation:||Journal of Rheumatology. Vol.37, No.7 (2010), 1422-1430|
|Abstract:||Objective. To develop recommendations for the use of methotrexate (MTX) in patients with rheumatoid arthritis. Methods. Canadian rheumatologists who participated in the international 3e Initiative in Rheumatology (evidence, expertise, exchange) in 2007-2008 formulated 5 unique Canadian questions. A bibliographic team systematically reviewed the relevant literature on these 5 topics. An expert committee consisting of 26 rheumatologists from across Canada was convened, and a set of recommendations was proposed based on the results of systematic reviews combined with expert opinions using a nominal group consensus process. Results. The 5 questions addressed drug interactions, predictors of response, strategies to reduce non-serious side effects, variables to assess clinical response, and incorporating patient preference into decision-making. The systematic review retrieved 93 pertinent articles; this evidence was presented to the expert committee during the interactive workshop. After extensive discussion and voting, a total of 9 recommendations were formulated: 2 on drug interactions, 1 on predictors of response, 2 on strategies to reduce non-serious side effects, 3 on variables to assess clinical response, and 1 on incorporating patient preferences into decision-making. The level of evidence and the strength of recommendations are reported. Agreement among panelists ranged from 85% to 100%. Conclusion. Nine recommendations pertaining to the use of MTX in daily practice were developed using an evidence-based approach followed by expert/physician consensus with high level of agreement. The Journal of Rheumatology Copyright © 2010. All rights reserved.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.